Sandbox:Hannan: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 295: Line 295:
|
|
|
|
*[[Headaches]]
*[[Palpitations]]
*Excessive [[sweating]]
*[[Anxiety]]
*[[Pallor]]
*Pain in [[chest]]/[[abdomen]]
*[[Weakness]], [[fatigue]]
*[[Nausea]]/[[vomiting]]
*[[Dizziness]]
*[[Paresthesias]]
*[[Constipation]] (rarely [[diarrhea]])
*[[Visual disturbance]]
|
|
|
|

Revision as of 17:44, 1 February 2019

Cortex Product Clinical manifestations Dianosis Gold

standard

Other features
Symptoms Signs Blood & Urine Histopathological Imaging Others
Adenoma Aldosterone[1][2][3][4]
  • Headache
  • Vision problems
  • Muscle cramps
  • Muscle weakness & cramps
  • Numbness
  • Temporary paralysis
  • Polyuria and polydipsia
  • Hypertension
  • Refractory hypertension
  • Hypokalemia
  • Alkalosis
  • ↑ Plasma aldosterone
  • ↓ Plasma Renin
  • ↑ ARR
  • Single or multiple nodules
  • Encapsulated
  • Abundant clear cytoplasm
  • Uniforming nuclei
  • Histopathology may resemble:
    • ZF (large, lipid-laden clear cells)
    • ZG (small, compact cells with moderate amount of lipid)
    • ZR (lipid-sparse cytoplasm)
  • Adrenal mass or nodule
  • Unilateral or bilateral adrenal atrophy
  • Hypodense mass (CT)
  • Iso and low FDG uptake compared with liver (FDG PET/CT)
  • Hyperintense on in-phase and hypointense on oppose-phase (MRI)
  • Fludrocortisone Suppression Testing
  • Oral Sodium Loading
  • Saline Infusion Testing
  • Captopril test
  • Adrenal venous sampling
  • Posture test
  • Genetic testing
  • Immunohistochemical staining
  • Fludrocortisone Suppression Testing
  • Glucocorticoid-Remediable Aldosteronism responds to glucocorticoids
  • Higher cardiovascular and cerebrovascular morbidity
Cortisol[1][5][6][7]
  • Weight gain
  • Growth retardation
  • Headaches
  • Amenorrhea
  • Virilization (rare)
  • Acne
  • Violaceous striae
  • Acanthosis nigricans
  • Sleep disruption
  • Mental changes
  • Muscular weakneness
  • Hypertension
  • Hirsutism
  • Hypogonadism
  • Growth retardation
  • Facial plethora
  • Acne
  • Striae
  • Bruising
  • Acanthosis nigricans
  • Mental changes
  • Muscular weakneness
  • ↑ Plasma cortisol
  • ↑ 24 Hour urinary cortisol
  • ↓ or inappropriately normal plasma ACTH
  • ↑ Blood glucose
  • Yellow fat
  • Brown discoloration
  • Large cells with increased lipid contetnt (zona fasciculata)
  • May contain pigment (lipofuscin)
  • Adjacent atrophied cells
  • Hemorrhage and calcification (Pre-malignant lesions)
  • Adrenal mass or nodule
  • Unilateral or bilateral adrenal atrophy
  • ↑ Fat
  • Hypodense mass (CT)
  • Iso and low FDG uptake compared with liver (FDG PET/CT)
  • Hyperintense on in-phase and hypointense on oppose-phase (MRI)
  • Diurnal plasma cortisol variation
  • Low dose and high dose dexamethasone suppression test
  • Dexamethasone-CRH test
  • Adrenal venous sampling
  • Genetic testing
  • Immunohistochemical staining
  • Dual-energy X-ray absorptiometry
  • N/A
  • Associated with Carney complex
  • Associated with MEN-1
  • Plasma levels of cortisol and ACTH may show false positive and false negative results due to normal diurnal hormonal variation
Androgens[4][8][9][10]
  • Hirsutism
  • Virilization
  • Amenorrhea
  • Precocious puberty
  • Testicular atrophy & diminished libido (male)
  • Clitorimegaly
  • Male pattern baldness
  • Resistant hypertension
  • Gynecomastia
  • ↑ Serum testosterone
  • ↑ Serum androstenedione
  • ↑ Serum dehydroepiandrosterone sulfate (DHEA-S)
  • ↑ urine 17-ketosteroids
  • ↑ plasma and urine estrogens
  • Pale tan to brown
  • Pseudocapsule or the fibrous capsule
  • Nesting, alveolar, cords, trabeculae
  • Eosinophilic cytoplasm
  • May see clear, vacuolated cytoplasm
  • Well-defined
  • Solid mass
  • Homogeneous enhancement (CT contrast)
  • Hyperintense on in-phase and hypointense on oppose-phase (MRI)
  • FSH, LH, prolactin levels
  • Cortisol levels
  • FDG PET/CT
  • Pelvic Ultrasound
  • Adrenal Venous sampling
  • N/A
  • Extremely rare
  • Most androgen secreting adenomas are mixed tumors
Non-functional[1][11][12][13]
  • Asymptomatic
  • Abdominal pain
  • Abdominal distenstion
  • Nausea/vomiting
  • Sub-clinical Cushing syndrome
  • Sub-clinical hyperaldosteroism
  • Asymptomatic
  • Abdominal asymmetry
  • Abdominal mass
  • Sub-clinical Cushing syndrome
  • Sub-clinical hyperaldosteroism
  • N/L
  • ↓ Adrenal hormones
  • ↑ Serum cortisol (sub-clinical)
  • ↑ Serum aldosterone (sub-clinical)
  • ↑ Serum androgens (sub-clinical)
  • Well-defined margins
  • Large monomorphic cells
  • Abundant/foamy cytoplasm
  • Typically resemble normal adrenal histology
  • May see hemorrhage & necrosis
  • Solid, well defined mass (ultrasound)
  • High lipid content and adjacent compression (CT)
  • Hyperintense on in-phase and hypointense on oppose-phase (MRI)
  • Adrenal hormone levels
  • Blood glucose level
  • Plasma catecholamines and urinary metanephrines
  • ARR
  • Immunohistochemical staining
  • N/A
  • 2-fold increased risk for Diabetes mellitus in some studies
  • Work up must exclude Cushing syndrome, pheochromocytoma and adrenal carcinoma
Carcinoma[12][14][15][16][17]
  • Symptoms of adrenal hormones as mentioned in adrenal adenomas
  • Constitutional symptoms such as cachexia, night sweats, fever
  • Localized symptoms such as abdominal pain, mass, fullness, early satiety
  • Hypertension
  • Signs of adrenal hormones as mentioned in adrenal adenomas
  • Constitutional
  • Localized signs such as abdominal mass,abdominal distension
  • N/L
  • ↑ Serum cortisol
  • ↑ Serum aldosterone
  • ↑ Serum androgens
  • Hypokalemia
  • Alkalosis
  • ↑ ARR
  • ↑ Blood glucose
  • brown to orange to yellow
  • Necrosis & mitosis
  • Hypercellular & solid and/or diffuse growth pattern
  • Low to high lipid content
  • Nuclear pleomorphism
  • Lymphovascular invasion
  • Heterogeneous enhancement (CT)
  • Heterogenous hyper-intensity (T2-weighted) and hypo-intensity on (T1-weighted) (MRI)
  • Heterogeneous mass with intense FDG uptake greater than liver ([18F]FDG PET/CT)
  • Serum ACTH
  • Low dose and high dose dexamethasone
  • Urinary adrenal metabolites
  • Proton MR spectroscopy
  • [11C]MTO PET
  • Immunohistochemical staining
  • N/A
  • May cause hypoglycemia (Anderson's syndrome}
  • May be associated with:
    • hyperreninemic
    • hyperaldosteronism,
    • erythropoietin-associated polycythemia
    • leukocytosis
Nodular

Hyperplasia

Medulla Product Clinical manifestations Dianosis Gold

standard

Other features
Symptoms Signs Blood & Urine Histopathological Imaging Others
Pheochromocytoma
Neuroblastoma
Ganglioneuroma

References

  1. 1.0 1.1 1.2 Park JJ, Park BK, Kim CK (June 2016). "Adrenal imaging for adenoma characterization: imaging features, diagnostic accuracies and differential diagnoses". Br J Radiol. 89 (1062): 20151018. doi:10.1259/bjr.20151018. PMC 5258164. PMID 26867466.
  2. Monticone S, Castellano I, Versace K, Lucatello B, Veglio F, Gomez-Sanchez CE, Williams TA, Mulatero P (August 2015). "Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas". Mol. Cell. Endocrinol. 411: 146–54. doi:10.1016/j.mce.2015.04.022. PMC 4474471. PMID 25958045.
  3. Stowasser M, Taylor PJ, Pimenta E, Ahmed AH, Gordon RD (May 2010). "Laboratory investigation of primary aldosteronism". Clin Biochem Rev. 31 (2): 39–56. PMC 2874431. PMID 20498828.
  4. 4.0 4.1 Guerrisi A, Marin D, Baski M, Guerrisi P, Capozza F, Catalano C (2013). "Adrenal lesions: spectrum of imaging findings with emphasis on multi-detector computed tomography and magnetic resonance imaging". J Clin Imaging Sci. 3: 61. doi:10.4103/2156-7514.124088. PMC 3935261. PMID 24605256.
  5. Stratakis CA (2008). "Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin- independent Cushing syndrome)". Endocr Dev. 13: 117–32. doi:10.1159/000134829. PMC 3132884. PMID 18493137.
  6. Zilbermint M, Stratakis CA (June 2015). "Protein kinase A defects and cortisol-producing adrenal tumors". Curr Opin Endocrinol Diabetes Obes. 22 (3): 157–62. doi:10.1097/MED.0000000000000149. PMC 4560837. PMID 25871963.
  7. Wei J, Li S, Liu Q, Zhu Y, Wu N, Tang Y, Li Q, Ren K, Zhang Q, Yu Y, An Z, Chen J, Li J (April 2018). "ACTH-independent Cushing's syndrome with bilateral cortisol-secreting adrenal adenomas: a case report and review of literatures". BMC Endocr Disord. 18 (1): 22. doi:10.1186/s12902-018-0250-6. PMC 5913873. PMID 29685132.
  8. Arnold DT, Reed JB, Burt K (January 2003). "Evaluation and management of the incidental adrenal mass". Proc (Bayl Univ Med Cent). 16 (1): 7–12. PMC 1200803. PMID 16278716.
  9. Rodríguez-Gutiérrez R, Bautista-Medina MA, Teniente-Sanchez AE, Zapata-Rivera MA, Montes-Villarreal J (2013). "Pure androgen-secreting adrenal adenoma associated with resistant hypertension". Case Rep Endocrinol. 2013: 356086. doi:10.1155/2013/356086. PMC 3681270. PMID 23819074.
  10. Zhou WB, Chen N, Li CJ (January 2019). "A rare case of pure testosterone-secreting adrenal adenoma in a postmenopausal elderly woman". BMC Endocr Disord. 19 (1): 14. doi:10.1186/s12902-019-0342-y. PMC 6343319. PMID 30674304.
  11. Lopez D, Luque-Fernandez MA, Steele A, Adler GK, Turchin A, Vaidya A (October 2016). ""Nonfunctional" Adrenal Tumors and the Risk for Incident Diabetes and Cardiovascular Outcomes: A Cohort Study". Ann. Intern. Med. 165 (8): 533–542. doi:10.7326/M16-0547. PMC 5453639. PMID 27479926.
  12. 12.0 12.1 Nieman LK (September 2010). "Approach to the patient with an adrenal incidentaloma". J. Clin. Endocrinol. Metab. 95 (9): 4106–13. doi:10.1210/jc.2010-0457. PMC 2936073. PMID 20823463.
  13. Li B, Guo Q, Yang H, Guan J (January 2013). "Giant non-functional adrenal adenoma: A case report". Oncol Lett. 5 (1): 378–380. doi:10.3892/ol.2012.978. PMC 3525484. PMID 23255953.
  14. Libé R (2015). "Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment". Front Cell Dev Biol. 3: 45. doi:10.3389/fcell.2015.00045. PMC 4490795. PMID 26191527.
  15. Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T (September 2018). "CT and MRI of adrenal gland pathologies". Quant Imaging Med Surg. 8 (8): 853–875. doi:10.21037/qims.2018.09.13. PMC 6177362. PMID 30306064.
  16. Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, Jolly S, Miller BS, Giordano TJ, Hammer GD (April 2014). "Adrenocortical carcinoma". Endocr. Rev. 35 (2): 282–326. doi:10.1210/er.2013-1029. PMC 3963263. PMID 24423978.
  17. Wang C, Sun Y, Wu H, Zhao D, Chen J (March 2014). "Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers". Histopathology. 64 (4): 567–76. doi:10.1111/his.12283. PMC 4282325. PMID 24102952.